STOCK TITAN

iTeos to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
iTeos Therapeutics, Inc. (ITOS) will participate in two investor conferences in March 2024, including Cowen 44th Annual Healthcare Conference and Leerink Partners Global Biopharma Conference. The company aims to showcase its immuno-oncology therapeutics for patients.
Positive
  • None.
Negative
  • None.

WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in March:

Cowen 44th Annual Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: Wednesday, March 6, 2024
Time: 1:30 PM ET
Location: Boston, M.A.

Leerink Partners Global Biopharma Conference
Format: One-on-one investor meetings
Date: Monday, March 11, 2024
Location: Miami, F.L.

A live webcast of the conference presentation will be available on the Investors section of the company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT:CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of Information

iTeos Therapeutics routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos Therapeutics.

For further information, please contact:

Investor Contact:

Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com

Media Contact:

media@iteostherapeutics.com


FAQ

When will iTeos Therapeutics participate in the Cowen 44th Annual Healthcare Conference?

iTeos Therapeutics will participate in the Cowen 44th Annual Healthcare Conference on Wednesday, March 6, 2024, at 1:30 PM ET in Boston, M.A.

Where will iTeos Therapeutics hold one-on-one investor meetings during the Leerink Partners Global Biopharma Conference?

iTeos Therapeutics will hold one-on-one investor meetings during the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024, in Miami, F.L.

Where can investors watch a live webcast of iTeos Therapeutics' conference presentation?

Investors can watch a live webcast of iTeos Therapeutics' conference presentation on the Investors section of the company’s website at www.iteostherapeutics.com.

For how long will an archived replay of iTeos Therapeutics' conference presentation be available?

An archived replay of iTeos Therapeutics' conference presentation will be available for approximately 30 days following the presentation.

iTeos Therapeutics, Inc.

NASDAQ:ITOS

ITOS Rankings

ITOS Latest News

ITOS Stock Data

652.02M
24.79M
0.54%
102.4%
5.71%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
WATERTOWN

About ITOS

starting operations in 2012, iteos therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iteos is developing eos200271, a clinical-stage potent and selective ido1 inhibitor with exceptional brain penetration. the company is also advancing eos100850, an insurmountable and non-brain penetrant adenosine a2a receptor antagonist, into a phase 1 trial in the second half of 2018; and a human adcc-enabling anti-tigit antibody (eos884448), representing an additional, third clinical entry in 2019. based in gosselies, belgium, iteos therapeutics was founded and supported in part by investments from the ludwig institute cancer research (licr), the walloon region of belgium and the european fund for economic and regional development (feder). for more information, please visit www.iteostherapeutics.com.